Authored by KFF’s Tricia Neuman, Juliette Cubanski and Larry Levitt, this post for Health Affairs Forefront examines how the outcomes of the first-ever Medicare drug value negotiations will generate financial savings for the federal government and for Medicare beneficiaries, and the way candidates’ views on the difficulty might play a task within the upcoming elections and in shaping the way forward for authorities negotiation of drug costs.
